Cited 26 times in
High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김준명 | - |
dc.date.accessioned | 2014-12-19T16:55:00Z | - |
dc.date.available | 2014-12-19T16:55:00Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0924-8579 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90433 | - |
dc.description.abstract | Failure of vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia has been reported despite full susceptibility of the organism to vancomycin. A retrospective observational cohort study including 137 patients with MRSA bacteraemia was performed at two centres in South Korea during 2009–2010. A total of 137 patients with MRSA bacteraemia receiving vancomycin therapy were enrolled during the study period. Isolates from 13 (9.5%) of the 137 patients had minimum inhibitory concentrations (MICs) ≥1 μg/mL. The 30-day cumulative survival was 53.8% for patients infected with isolates having a MIC ≥ 1 μg/mL and 79.8% for patients infected with isolates having a MIC < 1 μg/mL (log-rank test, P = 0.026). Vancomycin MIC ≥ 1 μg/mL [hazard ratio (HR) = 7.0, 95% confidence interval (CI) 2.2–22.1; P = 0.001], nosocomial acquisition of bacteraemia (HR = 5.4, 95% CI 1.4–20.1; P = 0.013), rapidly fatal underlying diseases (HR = 20.5, 95% CI 3.9–106.4; P < 0.001), presentation with septic shock (HR = 8.4, 95% CI 3.0–23.3; P < 0.001), presence of complicated infections (HR = 5.6, 95% CI 2.0–15.8; P = 0.001) and persistent MRSA bacteraemia for ≥3 days (HR = 4.2, 95% CI 1.4–12.7; P = 0.012) were independent predictors of 30-day mortality in patients with MRSA bacteraemia. In patients with high Pitt bacteraemia scores (Pitt score ≥2), the delay in initiation of vancomycin therapy was significantly different between non-survivors and survivors (2.4 days vs. 1.1 days; P = 0.012). Vancomycin MIC ≥ 1 μg/mL had a significant impact on mortality of patients with MRSA bacteraemia. These findings support early consideration of alternative anti-MRSA agents in patients with MRSA bacteraemia who have high vancomycin MICs as well as prompt initiation of anti-MRSA treatment in patients with MRSA bacteraemia, especially those with high Pitt scores. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anti-Bacterial Agents/administration & dosage | - |
dc.subject.MESH | Anti-Bacterial Agents/pharmacology | - |
dc.subject.MESH | Bacteremia/drug therapy | - |
dc.subject.MESH | Bacteremia/microbiology | - |
dc.subject.MESH | Bacteremia/mortality* | - |
dc.subject.MESH | Confidence Intervals | - |
dc.subject.MESH | Cross Infection/drug therapy | - |
dc.subject.MESH | Cross Infection/microbiology | - |
dc.subject.MESH | Cross Infection/mortality | - |
dc.subject.MESH | Drug Resistance, Bacterial* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Methicillin-Resistant Staphylococcus aureus/drug effects | - |
dc.subject.MESH | Methicillin-Resistant Staphylococcus aureus/pathogenicity* | - |
dc.subject.MESH | Microbial Sensitivity Tests | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Shock, Septic/drug therapy | - |
dc.subject.MESH | Shock, Septic/microbiology | - |
dc.subject.MESH | Shock, Septic/mortality | - |
dc.subject.MESH | Staphylococcal Infections/drug therapy | - |
dc.subject.MESH | Staphylococcal Infections/microbiology | - |
dc.subject.MESH | Staphylococcal Infections/mortality* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vancomycin/administration & dosage* | - |
dc.subject.MESH | Vancomycin/pharmacology | - |
dc.title | High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yu Mi Wi | - |
dc.contributor.googleauthor | June Myung Kim | - |
dc.contributor.googleauthor | Eun-Jeong Joo | - |
dc.contributor.googleauthor | Young Eun Ha | - |
dc.contributor.googleauthor | Cheol-In Kang | - |
dc.contributor.googleauthor | Kwan Soo Ko | - |
dc.contributor.googleauthor | Doo Ryeon Chung | - |
dc.contributor.googleauthor | Jae-Hoon Song | - |
dc.contributor.googleauthor | Kyong Ran Peck | - |
dc.identifier.doi | 10.1016/j.ijantimicag.2012.04.003 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00953 | - |
dc.relation.journalcode | J01088 | - |
dc.identifier.eissn | 1872-7913 | - |
dc.identifier.pmid | 22633565 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0924857912001616 | - |
dc.subject.keyword | MRSA bacteraemia | - |
dc.subject.keyword | Vancomycin | - |
dc.subject.keyword | MIC | - |
dc.subject.keyword | Mortality | - |
dc.contributor.alternativeName | Kim, June Myung | - |
dc.contributor.affiliatedAuthor | Kim, June Myung | - |
dc.citation.volume | 40 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 108 | - |
dc.citation.endPage | 113 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, Vol.40(2) : 108-113, 2012 | - |
dc.identifier.rimsid | 32759 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.